小细胞肺癌中是否存在任何诊疗生物标志物？
Are there any theranostic biomarkers in small cell lung carcinoma?
作者信息
Pezzuto Federica, Fortarezza Francesco, Lunardi Francesca, Calabrese Fiorella
机构信息
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, Padova, Italy.
出版信息
J Thorac Dis. 2019 Jan;11(Suppl 1):S102-S112. doi: 10.21037/jtd.2018.12.14.
Abstract
Small cell lung cancer (SCLC), an aggressive lung tumour with a poor prognosis, has a high load of somatic mutations, mainly induced by tobacco carcinogens given the strong association with smoking. Advances in genomic, epigenetic and proteomic profiling have significantly improved our understanding of the molecular and cellular biology of SCLC. Given the high mutational burden of SCLC the immune microenvironment is another exciting area under investigation even if it seems to be quite distinct from that of other solid tumours. In this review we will outline the current progress in molecular etiology of SCLC mentioning some key markers considered promising theranostic biomarkers.
摘要
小细胞肺癌（SCLC）是一种侵袭性强、预后差的肺部肿瘤，具有高负荷的体细胞突变，鉴于其与吸烟的密切关联，主要由烟草致癌物诱发。基因组、表观遗传学和蛋白质组学分析的进展显著提高了我们对SCLC分子和细胞生物学的理解。鉴于SCLC的高突变负担，免疫微环境是另一个令人兴奋的研究领域，即使它似乎与其他实体瘤的免疫微环境截然不同。在本综述中，我们将概述SCLC分子病因学的当前进展，并提及一些被认为有望成为治疗诊断生物标志物的关键标志物。
相似文献
1
Are there any theranostic biomarkers in small cell lung carcinoma?小细胞肺癌中是否存在任何诊疗生物标志物？
J Thorac Dis. 2019 Jan;11(Suppl 1):S102-S112. doi: 10.21037/jtd.2018.12.14.
2
Personalized Therapy of Small Cell Lung Cancer.小细胞肺癌的个体化治疗
Adv Exp Med Biol. 2016;890:149-74. doi: 10.1007/978-3-319-24932-2_9.
3
Prospects of targeted and immune therapies in SCLC.小细胞肺癌的靶向和免疫治疗前景。
Expert Rev Anticancer Ther. 2019 Feb;19(2):151-167. doi: 10.1080/14737140.2019.1559057. Epub 2018 Dec 28.
4
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.上皮-间质转化（EMT）、ATM和SLFN11的动态变化决定了小细胞肺癌对PARP抑制剂和顺铂的反应。
Oncotarget. 2017 Apr 25;8(17):28575-28587. doi: 10.18632/oncotarget.15338.
5
A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.肺外周、小细胞型高级神经内分泌肿瘤的临床病理研究：小细胞肺癌与大细胞神经内分泌癌的区别。
Eur J Cardiothorac Surg. 2012 Apr;41(4):841-6. doi: 10.1093/ejcts/ezr132. Epub 2011 Dec 21.
6
Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.小细胞肺癌（SCLC）与肺类癌肿瘤的差异蛋白质组学分析揭示了肺癌恶性肿瘤的分子特征。
Proteomics Clin Appl. 2018 Nov;12(6):e1800015. doi: 10.1002/prca.201800015. Epub 2018 Jul 5.
7
8
Progress and challenges in the treatment of small cell lung cancer.小细胞肺癌治疗的进展与挑战
Med Oncol. 2017 Jun;34(6):110. doi: 10.1007/s12032-017-0966-6. Epub 2017 Apr 29.
9
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.肺大细胞神经内分泌癌的下一代测序揭示了小细胞癌样和非小细胞癌样亚组。
Clin Cancer Res. 2016 Jul 15;22(14):3618-29. doi: 10.1158/1078-0432.CCR-15-2946. Epub 2016 Mar 9.
10
Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.挑战难治性疾病——为小细胞肺癌开发分子驱动的治疗方法。
Eur J Cancer. 2019 Sep;119:132-150. doi: 10.1016/j.ejca.2019.04.037. Epub 2019 Aug 21.
引用本文的文献
1
Urinary exosomal RAB11A serves as a novel non-invasive biomarker for diagnosis, treatment response monitoring, and prognosis in small cell lung cancer.尿外泌体RAB11A作为一种新型非侵入性生物标志物，用于小细胞肺癌的诊断、治疗反应监测及预后评估。
Clin Proteomics. 2025 Aug 25;22(1):30. doi: 10.1186/s12014-025-09554-4.
2
The role of pathologists in the diagnosis of occupational lung diseases: an expert opinion of the European Society of Pathology Pulmonary Pathology Working Group.病理学家在职业性肺部疾病诊断中的作用：欧洲病理学会肺部病理学工作组的专家意见。
Virchows Arch. 2024 Aug;485(2):173-195. doi: 10.1007/s00428-024-03845-1. Epub 2024 Jul 20.
3
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.癌基因依赖型非小细胞肺癌的形态-分子转化。
Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164.
4
Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights.腹膜间皮瘤的分子途径：新见解的简要综述
Front Oncol. 2022 Feb 10;12:823839. doi: 10.3389/fonc.2022.823839. eCollection 2022.
5
Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics.通过定量蛋白质组学分析小细胞肺癌中的循环微泡和外泌体
Clin Proteomics. 2022 Jan 7;19(1):2. doi: 10.1186/s12014-021-09339-5.
6
Synergistic alterations in the multilevel chromatin structure anchor dysregulated genes in small cell lung cancer.多级染色质结构的协同改变使小细胞肺癌中的失调基因得以锚定。
Comput Struct Biotechnol J. 2021 Nov 3;19:5946-5959. doi: 10.1016/j.csbj.2021.11.003. eCollection 2021.
7
Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer.小细胞肺癌液体活检的现状与未来展望
Biomedicines. 2021 Jan 7;9(1):48. doi: 10.3390/biomedicines9010048.
8
Radiotherapy in combination with systemic therapies for brain metastases: current status and progress.放疗联合全身治疗脑转移瘤：现状与进展。
Cancer Biol Med. 2020 Nov 15;17(4):910-922. doi: 10.20892/j.issn.2095-3941.2020.0109. Epub 2020 Dec 15.
9
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.循环肿瘤DNA作为接受阿替唑单抗治疗的小细胞肺癌患者的预后决定因素
J Clin Med. 2020 Nov 27;9(12):3861. doi: 10.3390/jcm9123861.
10
The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer.DNA损伤修复途径与基因组稳定性在肺癌中的治疗潜力
Front Oncol. 2020 Jul 28;10:1256. doi: 10.3389/fonc.2020.01256. eCollection 2020.
本文引用的文献
1
Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.一线治疗的小细胞肺癌（SCLC）患者循环肿瘤细胞（CTC）中 Bcl-2 的表达。
Lung Cancer. 2018 Oct;124:270-278. doi: 10.1016/j.lungcan.2018.08.021. Epub 2018 Aug 27.
2
Clinical value of carcinoembryonic antigen for predicting the incidence of brain metastases and survival in small cell lung cancer patients treated with prophylactic cranial irradiation.癌胚抗原在预测接受预防性颅脑照射的小细胞肺癌患者脑转移发生率和生存率方面的临床价值。
Cancer Manag Res. 2018 Sep 4;10:3199-3205. doi: 10.2147/CMAR.S175043. eCollection 2018.
3
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.罗华比妥珠单抗特西利单抗：一种新型的 DLL3 靶向抗体药物偶联物。
Drugs R D. 2018 Dec;18(4):255-258. doi: 10.1007/s40268-018-0247-7.
4
BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small-cell lung cancer.BLACAT1预测小细胞肺癌预后不良并作为致癌性长链非编码RNA发挥作用。
J Cell Biochem. 2019 Feb;120(2):2540-2546. doi: 10.1002/jcb.27548. Epub 2018 Sep 11.
5
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.免疫微环境在小细胞肺癌中的作用：PD-L1 表达的分布和 FOXP3 阳性肿瘤浸润淋巴细胞的预后作用。
Eur J Cancer. 2018 Sep;101:191-200. doi: 10.1016/j.ejca.2018.06.023. Epub 2018 Aug 1.
6
Programmed death-ligand 1 positivity can predict improved survival and a lower risk of brain metastasis in patients with resectable small cell lung cancer.程序性死亡配体1阳性可预测可切除小细胞肺癌患者的生存改善及脑转移风险降低。
Oncol Lett. 2018 Aug;16(2):2373-2381. doi: 10.3892/ol.2018.8895. Epub 2018 Jun 4.
7
Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer.血清乳酸脱氢酶水平在小细胞肺癌随访中潜在效用的临床评估
J Cancer Res Ther. 2018 Jun;14(Supplement):S336-S340. doi: 10.4103/0973-1482.168994.
8
The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.血清神经元特异性烯醇化酶和乳酸脱氢酶在接受一线铂类化疗的小细胞肺癌患者中的预后价值。
Medicine (Baltimore). 2017 Nov;96(46):e8258. doi: 10.1097/MD.0000000000008258.
9
A long non-coding RNA HOTTIP expression is associated with disease progression and predicts outcome in small cell lung cancer patients.长非编码 RNA HOTTIP 的表达与疾病进展相关，并可预测小细胞肺癌患者的预后。
Mol Cancer. 2017 Oct 17;16(1):162. doi: 10.1186/s12943-017-0729-1.
10
Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.由Mir-30a-5p低表达介导的增强型Beclin-1促进人小细胞肺癌的化疗耐药性。
Cell Physiol Biochem. 2017;43(3):1126-1139. doi: 10.1159/000481754. Epub 2017 Oct 5.
Zotero 插件